Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23.

PMID:
22098079
[PubMed - indexed for MEDLINE]
2.

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.

Poveda E, de Mendoza C, Parkin N, Choe S, García-Gasco P, Corral A, Soriano V.

AIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.

PMID:
18317002
[PubMed - indexed for MEDLINE]
3.

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.

Spagnuolo V, Gianotti N, Seminari E, Galli L, Fusetti G, Salpietro S, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):192-5. doi: 10.1097/QAI.0b013e31819367fc.

PMID:
19131889
[PubMed - indexed for MEDLINE]
4.

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2473-9. doi: 10.1128/AAC.00096-10. Epub 2010 Apr 5.

PMID:
20368406
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.

Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.

Int J STD AIDS. 2011 Nov;22(11):617-20. doi: 10.1258/ijsa.2009.009007.

PMID:
22096044
[PubMed - indexed for MEDLINE]
6.

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P.

AIDS. 2008 Sep 12;22(14):1809-13. doi: 10.1097/QAD.0b013e328307f24a.

PMID:
18690163
[PubMed - indexed for MEDLINE]
7.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.

PMID:
18039922
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.

BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154.

PMID:
19751502
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.

Yeni P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S91-4. Review.

PMID:
14562864
[PubMed - indexed for MEDLINE]
10.

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Luna B, Townsend MU.

Clin Ther. 2007 Nov;29(11):2309-18. Review.

PMID:
18158073
[PubMed - indexed for MEDLINE]
11.

Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

Antoniou T, Raboud JM, Diong C, Su D, Dewhurst N, Buckley V, Kovacs C, Rachlis A, Brunetta J, Smith G, Gough K, Fletcher D, Loutfy MR.

J Int Assoc Physicians AIDS Care (Chic). 2010 Nov-Dec;9(6):382-9. doi: 10.1177/1545109710382041.

PMID:
21138833
[PubMed - indexed for MEDLINE]
12.

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.

J Virol. 2006 Nov;80(21):10794-801. Epub 2006 Aug 23.

PMID:
16928764
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.

Vidal JE, Freitas AC, Song AT, Campos SV, Dalben M, Hernandez AV.

Braz J Infect Dis. 2011 May-Jun;15(3):245-8.

PMID:
21670925
[PubMed - indexed for MEDLINE]
Free Article
14.

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08. Epub 2008 Jul 14.

PMID:
18625773
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G.

AIDS. 2000 Sep 8;14(13):1943-8.

PMID:
10997398
[PubMed - indexed for MEDLINE]
16.

HIV-1 protease mutations and protease inhibitor cross-resistance.

Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW.

Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.

PMID:
20660676
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.

Elgadi MM, Piliero PJ.

Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000.

PMID:
22007990
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group.

Clin Infect Dis. 2006 Nov 15;43(10):1337-46. Epub 2006 Oct 17.

PMID:
17051503
[PubMed - indexed for MEDLINE]
Free Article
19.

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.

de Mendoza C, Morelló J, Garcia-Gascó P, Rodríguez-Novoa S, Soriano V.

Expert Opin Pharmacother. 2007 Apr;8(6):839-50.

PMID:
17425479
[PubMed - indexed for MEDLINE]
20.

Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.

Mata-Munguía C, Escoto-Delgadillo M, Torres-Mendoza B, Flores-Soto M, Vázquez-Torres M, Gálvez-Gastelum F, Viniegra-Osorio A, Castillero-Manzano M, Vázquez-Valls E.

BMC Bioinformatics. 2014 Mar 15;15:72. doi: 10.1186/1471-2105-15-72.

PMID:
24629078
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk